Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Postgrad Med J ; 99(1167): 25-31, 2023 Mar 22.
Article in English | MEDLINE | ID: covidwho-2288920

ABSTRACT

BACKGROUND: Simulation via Instant Messaging-Birmingham Advance (SIMBA) delivers simulation-based learning through WhatsApp and Zoom, helping to sustain continuing medical education (CME) for postgraduate healthcare professionals otherwise disrupted by the coronavirus (COVID-19) pandemic. This study aimed to assess whether SIMBA helped to improve clinical knowledge and if this improvement in knowledge was sustained over time. METHODS: Two SIMBA sessions-thyroid and pituitary-were conducted in July-August 2020. Each session included simulation of various real-life cases and interactive discussion. Participants' self-reported confidence, acceptance, and knowledge were measured using surveys and multiple-choice questions pre- and post-simulation and in a 6- to 12-week follow-up period. The evaluation surveys were designed using Moore's 7 Levels of CME Outcomes Framework. RESULTS: A total of 116 participants were included in the analysis. Significant improvement was observed in participants' self-reported confidence in approach to simulated cases (thyroid, n = 37, P < .0001; pituitary, n = 79, P < .0001). Significant improvement in clinical knowledge was observed following simulation (thyroid, n = 37, P < .0001; pituitary, n = 79, P < .0001). For both sessions, retention of confidence and knowledge was seen at 6-12 weeks' follow-up. CONCLUSIONS: SIMBA increased participants' clinical knowledge on simulated cases and this improvement was retained up to 6-12 weeks after the session. Further studies are required to explore long-term retention and whether it translates to improved real-world clinical practice.


Subject(s)
COVID-19 , Humans , COVID-19/epidemiology , Health Personnel/education , Education, Medical, Continuing , Clinical Competence
2.
Clinical Medicine ; 21:S34-S35, 2021.
Article in English | ProQuest Central | ID: covidwho-1380288

ABSTRACT

Simulation-based learning is a useful teaching modality to develop clinicians' knowledge and skills, while protecting patients from harm.1 While simulation has traditionally occurred via face-to-face role play, many of its principles can be adapted for remote learning. The aim of this study was to explore the effectiveness of Simulation via Instant Messaging - Birmingham Advance (SIMBA) as a model of virtual simulation-based medical education during the COVID-19 pandemic. There was a significant improvement in selfreported confidence in participants' approach to the simulated cases (overall (204;p<0.001);adrenal (33;p<0.001);thyroid (37;p<0.001);pituitary (79;p<0.001);inflammatory bowel disease (17;p<0.001);acute medicine (38;p<0.001)).

3.
J R Coll Physicians Edinb ; 51(2): 168-172, 2021 06.
Article in English | MEDLINE | ID: covidwho-1271024

ABSTRACT

BACKGROUND: Simulation via Instant Messaging - Birmingham Advance (SIMBA) aimed to improve clinicians' confidence in managing various clinical scenarios during the COVID-19 pandemic. METHODS: Five SIMBA sessions were conducted between May and August 2020. Each session included simulation of scenarios and interactive discussion. Participants' self-reported confidence, acceptance, and relevance of the simulated cases were measured. RESULTS: Significant improvement was observed in participants' self-reported confidence (overall n = 204, p<0.001; adrenal n = 33, p<0.001; thyroid n = 37, p<0.001; pituitary n = 79, p<0.001; inflammatory bowel disease n = 17, p<0.001; acute medicine n = 38, p<0.001). Participants reported improvements in clinical competencies: patient care 52.0% (n = 106/204), professionalism 30.9% (n = 63/204), knowledge on patient management 84.8% (n = 173/204), systems-based practice 48.0% (n = 98/204), practice-based learning 69.6% (n = 142/204) and communication skills 25.5% (n = 52/204). CONCLUSION: SIMBA is a novel pedagogical virtual simulation-based learning model that improves clinicians' confidence in managing conditions across various specialties.


Subject(s)
COVID-19 , Education, Distance , Education, Medical , Simulation Training/methods , Clinical Competence , Curriculum , Humans , Pandemics , SARS-CoV-2
5.
Eur J Endocrinol ; 183(1): G17-G23, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-205229

ABSTRACT

Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during the times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for too long. Furthermore, the majority of patients with pituitary tumours have co-morbidities potentially impacting the course and management of COVID-19 (e.g. hypopituitarism, diabetes mellitus, hypertension, obesity and cardiovascular disease). Here, we summarize some of the diagnostic and management dilemmas encountered, and provide guidance on safe and as effective as possible delivery of care in the COVID-19 era. We also attempt to address how pituitary services should be remodelled in the event of similar crises, while maintaining or even improving patient outcomes. Regular review of these recommendations and further adjustments are needed, depending on the evolution of the COVID-19 pandemic status. We consider that the utilization of successful models of pituitary multidisciplinary care implemented during the COVID-19 pandemic should continue after the crisis is over by using the valuable and exceptional experience gained during these challenging times.


Subject(s)
Adenoma/therapy , Antineoplastic Agents, Hormonal/therapeutic use , Coronavirus Infections , Dopamine Agonists/therapeutic use , Neurosurgical Procedures , Pandemics , Pituitary Apoplexy/therapy , Pituitary Neoplasms/therapy , Pneumonia, Viral , Adenoma/diagnosis , COVID-19 , Cabergoline/therapeutic use , Disease Management , Hormone Replacement Therapy , Human Growth Hormone/analogs & derivatives , Human Growth Hormone/therapeutic use , Humans , Octreotide/therapeutic use , Peptides, Cyclic/therapeutic use , Pituitary Apoplexy/diagnosis , Pituitary Neoplasms/diagnosis , Practice Guidelines as Topic , Radiotherapy , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Telemedicine , Time Factors , Visual Field Tests
SELECTION OF CITATIONS
SEARCH DETAIL